Article Versions Notes

Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, et al. Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics. 2020; 12(10):996. https://doi.org/10.3390/pharmaceutics12100996

Kamoun, Walid, Elden Swindell, Christine Pien, Lia Luus, Jason Cain, Minh Pham, Irawati Kandela, Zhaohua Richard Huang, Suresh K. Tipparaju, Alexander Koshkaryev, and et al. 2020. "Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic" Pharmaceutics 12, no. 10: 996. https://doi.org/10.3390/pharmaceutics12100996

Kamoun, W., Swindell, E., Pien, C., Luus, L., Cain, J., Pham, M., Kandela, I., Huang, Z. R., Tipparaju, S. K., Koshkaryev, A., Askoxylakis, V., Kirpotin, D. B., Bloom, T., Mino-Kenudson, M., Marks, J. D., Zalutskaya, A., Bshara, W., Morrison, C., & Drummond, D. C. (2020). Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics, 12(10), 996. https://doi.org/10.3390/pharmaceutics12100996